Makana Therapeutics
Developer of gene-edited swine and associated assays intended to enable pig-to-human transplantation. The organization focuses on removal of pig xenoantigen genes, optimized cloning and reproduction methods to produce clinical-grade animals, development and validation of histocompatibility and pathogen-screening assays, and IND-enabling preclinical xenotransplantation studies in preparation for human trials.
Industries
Nr. of Employees
small (1-50)
Products
Gene-edited pigs with reduced xenoantigen expression
Swine genetically modified to eliminate key xenoantigen genes (triple-gene knockout and additional SLA DR knockout) intended to reduce human antibody binding and organ rejection risk.
Gene-edited pigs with reduced xenoantigen expression
Swine genetically modified to eliminate key xenoantigen genes (triple-gene knockout and additional SLA DR knockout) intended to reduce human antibody binding and organ rejection risk.
Services
Design and execution of translational large-animal xenotransplantation experiments to evaluate graft survival, immunosuppression regimens, and candidate organ genetics.
Histocompatibility and crossmatch assays to identify human patients with low or no pre-existing anti-pig antibodies for potential xenotransplant eligibility.
Molecular diagnostic screening and assay development for a panel of pathogens relevant to animal donors and human recipients.
Production and scaled breeding of gene-edited pigs engineered to reduce xenoantigen expression for use in preclinical research and planned clinical programs.
Design and execution of translational large-animal xenotransplantation experiments to evaluate graft survival, immunosuppression regimens, and candidate organ genetics.
Histocompatibility and crossmatch assays to identify human patients with low or no pre-existing anti-pig antibodies for potential xenotransplant eligibility.
Molecular diagnostic screening and assay development for a panel of pathogens relevant to animal donors and human recipients.
Production and scaled breeding of gene-edited pigs engineered to reduce xenoantigen expression for use in preclinical research and planned clinical programs.
Expertise Areas
- Xenotransplantation
- Genetic engineering of donor animals
- Large-animal preclinical transplant models
- Histocompatibility and crossmatch testing
Key Technologies
- CRISPR/Cas9 gene editing
- Gene knockout strategies
- Somatic cell nuclear transfer (SCNT) / cloning
- Flow cytometry
News & Updates
Preclinical collaboration with a biopharmaceutical partner to study an anti-CD40L monoclonal antibody in combination with gene-edited organs to support IND-enabling studies.
Announcement of discovery of an additional gene knockout in pigs intended to reduce early organ rejection and plans for a definitive preclinical study and a first-in-human kidney trial pending regulatory approval.
Report of a patent grant in South Korea covering the triple-gene knockout pig; company also reported earlier European patent.
Award from KidneyX to continue development of genetically engineered donor pigs for kidney transplantation.
Announcement of an important European patent covering the triple-gene knockout pig.
Corporate headquarters moved to Miami to align operations with a major transplant institute collaboration.
Preclinical collaboration with a biopharmaceutical partner to study an anti-CD40L monoclonal antibody in combination with gene-edited organs to support IND-enabling studies.
Announcement of discovery of an additional gene knockout in pigs intended to reduce early organ rejection and plans for a definitive preclinical study and a first-in-human kidney trial pending regulatory approval.
Report of a patent grant in South Korea covering the triple-gene knockout pig; company also reported earlier European patent.
Award from KidneyX to continue development of genetically engineered donor pigs for kidney transplantation.
Announcement of an important European patent covering the triple-gene knockout pig.
Corporate headquarters moved to Miami to align operations with a major transplant institute collaboration.